Cargando…

Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis

BACKGROUND AND OBJECTIVE: Unresectable hepatocellular carcinoma (uHCC) is the main histological subtype of liver cancer and causes a great disease burden in China. We aimed to evaluate the cost-effectiveness of five first-line systemic treatments newly approved in the Chinese market for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Mingye, Pan, Xingming, Yin, Yue, Hu, Hongfei, Wei, Jifu, Bai, Zhaoshi, Tang, Wenxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051228/ https://www.ncbi.nlm.nih.gov/pubmed/35493395 http://dx.doi.org/10.3389/fpubh.2022.869960

Ejemplares similares

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
por: Meng, Rui, et al.
Publicado: (2022)

Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China
por: Ren, Yinan, et al.
Publicado: (2022)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
por: Zhao, Mingye, et al.
Publicado: (2023)

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective
por: Jiang, Yunlin, et al.
Publicado: (2023)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China
por: Ke, Xiatong, et al.
Publicado: (2021)

A Cost-Effectiveness Analysis of Comprehensive Smoking-Cessation Interventions Based on the Community and Hospital Collaboration
por: Qin, Tingting, et al.
Publicado: (2022)

Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis
por: Yin, Yue, et al.
Publicado: (2022)

Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis
por: Moll, Matthias, et al.
Publicado: (2023)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Does Economic Policy Uncertainty Matter for Healthcare Expenditure in China? A Spatial Econometric Analysis
por: Bai, Pu, et al.
Publicado: (2021)

Estimating the economic costs of Indigenous health inequities in New Zealand: a retrospective cohort analysis
por: Reid, Papaarangi, et al.
Publicado: (2022)

Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
por: Zhang, Donger, et al.
Publicado: (2021)

Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review
por: Zou, Huimin, et al.
Publicado: (2022)

Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China
por: Liang, Leyi, et al.
Publicado: (2023)

Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
por: Shao, Guoliang, et al.
Publicado: (2022)

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
por: Schattenberg, Jörn M., et al.
Publicado: (2021)

Economic Costs Associated with Motorbike Accidents in Kathmandu, Nepal
por: Sapkota, Diksha, et al.
Publicado: (2016)

Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: A network meta-analysis
por: Shao, Taihang, et al.
Publicado: (2023)

Economic Burden of Major Diseases in China in 2013
por: Song, Xianyan, et al.
Publicado: (2021)

Analysis on the Economic Recovery in the Post-COVID-19 Era: Evidence From China
por: Jiang, Dayang, et al.
Publicado: (2022)

Cost-effectiveness analysis of vaccination against COVID-19 in China
por: Zhou, Huixuan, et al.
Publicado: (2023)

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis
por: Chen, Xi, et al.
Publicado: (2023)

An Analysis of the Ethical, Economic, and Environmental Aspects of Entomophagy
por: Illa, Jofre, et al.
Publicado: (2022)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Cost analysis of childhood hematopoietic stem cell transplantation in Sichuan, China
por: Chen, Min, et al.
Publicado: (2023)

Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria
por: Ignatova, Valentina, et al.
Publicado: (2022)

Economic costs of gender inequality in health and the labor market: India's untapped potential
por: Khan, Aqeel, et al.
Publicado: (2023)

An analysis of the etiologies and economic indexes of inpatients with stage 5 chronic kidney disease in North China
por: Guo, Shan-Shan, et al.
Publicado: (2022)

The Economic Burden of Hospital Costs on Families With Type 1 Diabetes Mellitus Children: The Role of Medical Insurance in Shandong Province, China
por: Wang, Siyuan, et al.
Publicado: (2022)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Optimal utilization of ecological economic resources and low-carbon economic analysis from the perspective of Public Health
por: Wang, Qi, et al.
Publicado: (2023)

Trends, influencing factors and prediction analysis of under-five and maternal mortality rates in China from 1991 to 2020
por: Zhang, Meng, et al.
Publicado: (2023)

Estimating the economic costs of ethnic health inequities: protocol for a prevalence-based cost-of-illness study in New Zealand (2003–2014)
por: Reid, Papaarangi, et al.
Publicado: (2018)

Cost-Effectiveness of Gliclazide-Based Intensive Glucose Control vs. Standard Glucose Control in Type 2 Diabetes Mellitus. An Economic Analysis of the ADVANCE Trial in Vietnam
por: Nguyen-Thi, Hai-Yen, et al.
Publicado: (2020)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

Identifying Big Five personality traits based on facial behavior analysis
por: Cai, Lei, et al.
Publicado: (2022)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9f4ugsv3ol1a5l7sapur68fiet